Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 322

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure

Open access
Hamdy, Neveen A T, Kanis, John A, Beneton, Monique N C, Brown, Colin B, Juttmann, Job R, Jordans, Johannes G M, Josse, Sylvie, Meyrier, Alain, Lins, Robert L, Fairey, Ian T·1995·BMJ

Abstract

Objective : To determine whether alfacalcidol—used in management of overt renal bone disease—may safely prevent renal bone disease when used earlier in course of renal failure. Design : Double blind, prospective, randomised, placebo controlled study. Setting : 17 nephrology centres from Belgium, France, the Netherlands, and the United Kingdom. Subjects : 176 patients aged 18–81 with mild to moderate chronic renal failure (creatinine clearance 15–50 ml/min) and with no clinical, biochemical, or radiographic evidence of bone disease. Interventions : Alfacalcidol 0.25 μg (titrated according to serum calcium concentration) or placebo given for two years. Main outcome measures : Quantitative histology of bone to assess efficacy of treatment and renal function to assess safety. Results : 132 patients had histological evidence of bone disease at start of study. Biochemical, radiographic, and histological indices of bone metabolism were similar for the 89 patients given alfacalcidol and the 87 controls given placebo. After treatment, mean serum alkaline phosphatase activity and intact parathyroid hormone concentration had increased by 13% and 126% respectively in controls but had not changed in patients given alfacalcidol (P<0.001). Hypercalcaemic episodes occurred in 10 patients given alfacalcidol (but responded to decreases in drug dose) and in three controls. Histological indices of bone turnover significantly improved in patients given alfacalcidol and significantly deteriorated in controls: among patients with abnormal bone histology before treatment, bone disease resolved in 23 (42%) of those given alfacalcidol compared with two (4%) of the controls (P<0.001). There was no difference in rate of progression of renal failure between the two groups. Conclusion : Early administration of alfacalcidol can safely and beneficially alter the natural course of renal bone disease in patients with mild to moderate renal failure. Key messages: Key messages Treating such patients with alfacalcidol (up to 1 μg/day for two years) significantly improved their osteomalacia and hyperparathyroid disease Treatment had no apparent adverse effect on renal function Hypercalcaemic episodes were uncommon and readily responded to decreases in drug dose Alfacalcidol might be used more widely for patients with moderate renal failure not yet needing dialysis

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.310.6976.358

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 322

Metadata

Authors
Hamdy, N. A. T., Kanis, J. A., Beneton, M. N. C., Brown, C. B., Juttmann, J. R., Jordans, J. G. M., Josse, S., Meyrier, A., Lins, R. L., & Fairey, I. T.
Venue
BMJ
Publisher
BMJ
Published
1995-02-11
Volume
310
Issue
6976
Pages
358-363
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
OpenAlex
W2063719550
Cited by
322
References
22
FWCI
7.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. https://app.cochat.ai/papers/10.1136/bmj.310.6976.358
The paper
Hamdy, N. A. T., Kanis, J. A., Beneton, M. N. C., Brown, C. B., Juttmann, J. R., Jordans, J. G. M., Josse, S., Meyrier, A., Lins, R. L., & Fairey, I. T. (1995). Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. https://doi.org/10.1136/bmj.310.6976.358

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.